Patents by Inventor Robert Swyka

Robert Swyka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tricyclic heterocycles as FGFR inhibitors
    Patent number: 11939331
    Abstract: The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: June 8, 2022
    Date of Patent: March 26, 2024
    Assignee: Incyte Corporation
    Inventors: Xin Li, Evan Styduhar, Robert Swyka, Oleg Vechorkin, Wenqing Yao
  • Tricyclic heterocycles as FGFR inhibitors
    Patent number: 11897891
    Abstract: The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: February 13, 2024
    Assignee: Incyte Corporation
    Inventors: Matthew S. McCammant, Evan Styduhar, Oleg Vechorkin, Robert Swyka, Wenqing Yao
  • BICYCLIC AMINE CDK12 INHIBITORS
    Publication number: 20230203010
    Abstract: The present application provides bicyclic amines that are inhibitors of cyclin-dependent kinase 12 (CDK12), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: December 2, 2022
    Publication date: June 29, 2023
    Inventors: Xin Li, Michael Liang, Evan Styduhar, Robert Swyka, Oleg Vechorkin, Anlai Wang, Lin You, Peng Zhao, Ke Zhang, Minh Nguyen
  • TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
    Publication number: 20230002384
    Abstract: The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: June 8, 2022
    Publication date: January 5, 2023
    Inventors: Robert Swyka, Evan Styduhar, Xin Li, Oleg Vechorkin, Wenqing Yao
  • TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
    Publication number: 20230002385
    Abstract: The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: June 8, 2022
    Publication date: January 5, 2023
    Inventors: Xin Li, Evan Styduhar, Robert Swyka, Oleg Vechorkin, Wenqing Yao
  • TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
    Publication number: 20210171535
    Abstract: The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: December 3, 2020
    Publication date: June 10, 2021
    Inventors: Matthew S. McCammant, Evan Styduhar, Oleg Vechorkin, Robert Swyka, Wenqing Yao